Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study,by Kim M,Kim TH,Shin DY,Lim DJ,Kim EY,Kim WB,Chung JH,Shong YK,Kim BH,and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340–348. DOI: 10.1089/thy.2017.0356